/Investor DB

F-Prime Capital — 2024 Investments

25 investments dated 2024 · listed companies and verified rows first · show all

Denali Therapeuticsdenalitherapeutics.cominNASDAQ: DNLISeries A · Feb 2024 · $220M

Denali Therapeutics develops therapeutics for neurodegenerative diseases.

BiotechHealthtechMedical DevicesSan Francisco, US

Marc Tessier-Lavigne(Founder)inAlexander O. Schuth(Executive Officer)inRyan J. Watts(President, Chief Executive Officer and Director)inCarole Ho(Executive Officer)inSteve E. Krognes(Director)inAlexander Schuth(Founder)

Co-investorsARCH Venture PartnersEcoR1 CapitalForesite CapitalGV (Google Ventures)Flagship PioneeringFlagship Ventures

Comanche Biopharmacomanchebiopharma.cominJan 2024 · $75M

Comanche Biopharma is a biopharmaceutical company developing an investigational siRNA medicine (CBP-4888) targeting a root cause of preterm preeclampsia in pregnant women.

BiotechFemTechHealthtechConcord, US

Mike Young(Founder)inT Scott Johnson(Founder)inPaul Antinori(Executive Officer)Allison August(Executive Officer)inThomas Scott Johnson(Executive Officer, Director)

BoardBrendan Bulik-Sullivan(Director)in

Board seatMuz MansuriKetan Patel· per SEC Form D

Co-investorsAtlas VentureGV (Google Ventures)Broadview VenturesLilly Asia VenturesNew Enterprise Associates (NEA)

Tripsuitetripsuite.cominSeed · Sep 2024 · $5M

TripSuite is a software platform for travel agencies that combines CRM, commission tracking, accounting, itinerary management, analytics, and workflow automation in one system.

SaaSTravel & HospitalityBrooklyn, US

Jacey Jones(Executive Officer, Director, Promoter)inChristopher John Graves(Executive Officer, Director, Promoter)

Board seatGaurav Tuli· per SEC Form D

Zenflowzenflow.comin𝕏Series B · Nov 2024 · $31.4M

Zenflow develops medical devices for treating benign prostatic hyperplasia (BPH) in men, founded from the Stanford Byers Center for Biodesign with a team experienced in medical device development and FDA regulation.

HealthtechMedical DevicesSan Francisco, US

Shreya Mehta(CTO)inNick Damiano(CEO)inJohn Beck(Executive Officer)in

BoardBryan Kim(Director)Blayne Roeder(Director)

Board seatRobert Weisskoff· per SEC Form D

Co-investorsAstiaCloudStone CapitalDorm RoomShangBay Capital LLCY CombinatorAgrolimen Ventures+15 more

Amber Therapeuticsamber-tx.cominSeries A · Jun 2024 · $100M

Amber Therapeutics develops medical technology focused on treating mixed urinary incontinence, advancing toward pivotal clinical trials in the US with expanded feasibility studies in Europe.

Medical Devices

Co-investorsIntuitive VenturesLightstone VenturesNew Enterprise Associates (NEA)Oxford Science Enterprises

AvenCellavencell.comin𝕏Series B · Oct 2024 · $110M

AvenCell Therapeutics develops next-generation cell therapies for hard-to-treat cancers, including solid tumors, combining switchable universal CAR-T technology with a CRISPR/Cas9-based allogeneic platform.

BiotechLongevityMedical Devices

Andrew Schiermeier(Chief Executive Officer)in

Co-investorsNovo HoldingsBlackstone Life SciencesEight Roads VenturesNYBC Ventures

Burroburro.aiin𝕏Jan 2024 · $24M

Burro builds autonomous robots for agricultural and outdoor operations that mow, tow, carry, and spray to automate manual labor tasks.

AgTechAI & Machine LearningRobotics

Terry Scott(Founder)inCharlie Andersen(Founder)Vibhor Sood(Founder)

Co-investorsAsimov VenturesCatalyst InvestorsCIBUS ENTERPRISE FUND II LPEverywhere VenturesFf Venture CapitalNextFab Ventures+6 more

Chaos Labschaoslabs.xyzin𝕏Aug 2024

Chaos Labs builds AI-driven intelligence and risk-management infrastructure that converts fragmented data into institutional-grade insights, offering risk simulations, parameter tuning, and oracle technology for crypto protocols and financial institutions.

AI & Machine LearningCrypto & Web3Data & Infrastructure

Omer Goldberg(Founder)in

Co-investorsBalaji SrinivasanBlueYard CapitalCoinbase VenturesGalaxy VenturesHaun VenturesLightspeed Venture Partners+14 more

Engrail Therapeuticsengrail.cominSeries B · Mar 2024 · $170M

Engrail Therapeutics is a clinical-stage pharmaceutical company developing precision-targeted therapeutics for neupropsychiatric and neurodevelopmental disorders.

BiotechDigital HealthMedical DevicesSan Diego, US

Stephen(Co-founder, EVP Research & Development and Chief Development Officer)Paul Cayer(Chief Financial Officer)inVikram(President and Chief Executive Officer)Kimberly(Chief Scientific Officer)Quentin(Chief Technical Officer)

Co-investorsForesite CapitalLongwood FundNorwest Venture PartnersPivotal Life SciencesRiverVest Venture PartnersYsios Capital+4 more

Expressableexpressable.cominMay 2024 · $26M

Expressable provides speech therapy services using research-based techniques with a focus on family engagement and accessibility.

Digital HealthHealthtechSaaSAustin, US

Nicholas Barbara(Executive Officer, Director)inLeanne Sherred(President and Chief Clinical Officer)inBenjamin Pincus(Executive Officer)inSpencer Magloff(Executive Officer)inRyan Hinojosa(Executive Officer)Brett Cook(Director)

Co-investorsDigitalis VenturesLerer HippeauNextView VenturesHarbourVest Partners (Canada)

Galatea Biogalatea.bioAug 2024 · $8M

Genomics company building a multi-ancestry biobank and AI-driven analytics for clinical genetic testing and drug discovery.

HealthtechMiami Lakes, US

Carlos D. Bustamante(Executive Officer, Director)inArthur Polk(Executive Officer)Alexander Ioannidis(Director)

BoardWale Ayeni(Director)inMohit Kaushal(Director)Nicholas Katsanis(Director)

Co-investorsCEI VenturesCitta CapitalFounder CollectiveFunction VenturesHelios Digital VenturesLifeX Ventures+4 more

Laurus Biolaurus.bioinDec 2024

Laurus Bio, a subsidiary of Laurus Labs, is a biomanufacturing company using precision fermentation and recombinant DNA technology to produce animal-origin-free recombinant proteins, growth factors, and cell-culture media supplements.

BiotechDeep TechFoodTechNew MaterialsBengaluru, IN

Subramani Ramachandrappa(Founder and Non-Executive Director)inRajesh Krishnamurthy(Executive Director & CEO)inKrishna Kalyan(Executive Director & COO)in

BoardDr. Satyanarayana Chava(Chairman)

Co-investorsEight Roads Ventures

Metserametsera.comin𝕏Nov 2024acquired by Pfizer

Metsera was a clinical-stage biotechnology company developing injectable and oral medicines for obesity and metabolic diseases, including next-generation GLP-1 and amylin-based therapies.

BiotechHealthtechMedical DevicesNew York, US

Clive A. Meanwell(Director)Christopher J. Visioli(Executive Officer)inBrian Hubbard(Executive Officer)inChristopher Whitten Bernard(Executive Officer, Director)Steven Marso(Executive Officer)Clive Meanwell(Founder)

Co-investorsAlpha Wave GlobalARCH Venture PartnersGV (Google Ventures)RA CapitalSoftBank Vision FundViking Global+5 more

nChroma Bionchromabio.comin𝕏Dec 2024

nChroma Bio develops in vivo targeted delivery and genetic engineering technologies for genetic medicine applications.

BiotechDeep TechMedical DevicesBoston, US

Luke Gilbert, PhD(Founder)Keith Joung, MD, PhD(Founder)David Liu, PhD(Founder)Angelo Lombardo, PhD(Founder)Luigi Naldini, MD, PhD(Founder)Jonathan Weissman, PhD

Co-investorsAtlas VentureNewpath Partners5AM VenturesARCH Venture PartnersDCVC (Data Collective)GV (Google Ventures)+11 more

Nocion Therapeuticsnociontx.comin𝕏Mar 2024

Nocion Therapeutics develops small molecule charged sodium channel blockers (nocions) designed to silence overactive sensory nerves.

BiotechHealthtechMedical DevicesWatertown, US

MATTHEW FRANKEL(Executive Officer)inPETER COUROSSI(Executive Officer)RICHARD BATYCKY(President and Chief Executive Officer)JAMES ELLIS(Executive Officer)MICHAEL LIPP(Executive Officer)inCHRISTOPHER SILBER(Executive Officer)in

Co-investorsCanaan PartnersLumira VenturesMission BiocapitalMonograph Capital PartnersOUP (Osage University Partners)

Odasevaodaseva.comin𝕏Jun 2024

Odaseva provides data management, backup, and protection tools built for large enterprises running Salesforce at scale.

Data & InfrastructureEnterprise SoftwareSaaSSan Francisco, US

Sovan Bin(CEO and Founder)in

Co-investorsCRESCENT COVE CAPITALEight Roads VenturesPartech VenturesSerenaEurazeoSerena Capital

Oncusp Therapeuticsoncusptx.cominSeries A · Jan 2024 · $100M

OnCusp Therapeutics develops oncology therapeutics for cancer treatment, including antibody-drug conjugates and small molecule compounds in clinical and preclinical stages.

BiotechMedical DevicesNew York, US

Dr. Bing Yuan(Co-Founder, Chief Executive Officer)Dr. Eric Slosberg(Co-Founder, Chief Development Officer)Dr. Andy Fu(Co-Founder, Chief Business Officer)Bing Yuan, Ph.D., MBA(Co-Founder, Chief Executive Officer)Eric Slosberg, Ph.D.(Co-Founder, Chief Development Officer)Andy Fu, PharmD, MBA(Co-Founder, Chief Business Officer)

Co-investorsOrbiMedCatalio Capital Management, LPSofinnova VenturesDe Novo VenturesInsight PartnersNVIDIA

Quantum Circuitsquantumcircuits.cominSeries B · May 2024 · $60MAcquired

Quantum Circuits develops superconducting quantum computers using dual-rail qubits with built-in error detection, designed to accelerate the path to fault-tolerant quantum computing.

Advanced ManufacturingDeep TechHardwareQuantum ComputingMadison, US

Rob Schoelkopf(Sterling Professor, Founder)inLuigi Frunzio(Founder)Ray SmetsinMichel Devoret(Founder)Robert Schoelkopf(Founder)

Co-investorsARCH Venture PartnersCanaan PartnersConnecticut InnovationsFitz Gate VenturesIn-Q-TelOUP (Osage University Partners)+2 more

RIPPL Careripplcare.comin𝕏Oct 2024Acquired

Rippl delivers evidence-based dementia care through a combination of technology and human support for people living with dementia and their families.

Digital HealthHealthtechSeattle, US

Kris Engskov(Co-founder & CEO)inRobert Nelsen(Co-Founder & Board Chair)Paul Engskov(Executive Officer, Director)

BoardHolly Maloney(Director)inIyah Romm(Director)Ryan Watts(Director)

Co-investors1843 CapitalARCH Venture PartnersCity LightEquitage Ventures, L.L.C.General CatalystGV (Google Ventures)+2 more

Shift Bioscienceshiftbioscience.comin𝕏Oct 2024

Shift Bioscience develops siRNA therapeutics for cell rejuvenation, using a target identification platform that has identified an anti-fibrotic candidate initially aimed at liver fibrosis.

AI & Machine LearningBiotechLongevityCambridge, GB

Daniel Ives(Founder & CEO)inBrendan Swain(Co-founder & CSO)in

Co-investorsIKJ CapitalKindred CapitalCambridge Innovation Capital

Space and Timespaceandtime.ioin𝕏Aug 2024

Space and Time provides blockchain indexing, secure offchain data, and zero-knowledge proofs for onchain financial applications.

Crypto & Web3Data & Infrastructure

Scott Dykstra(Founder)in

Co-investorsAlliance DAO (ex DeFi Alliance)Alumni VenturesArrington CapitalCircle VenturesDigital Currency GroupEterna Capital+12 more

Tokutokueyes.cominApr 2024 · $9.3M

Toku Eyes develops AI-driven solutions for eye health diagnostics and monitoring, bringing together medical expertise in endocrinology and ophthalmology with artificial intelligence capabilities.

AI & Machine LearningDigital HealthHealthtechMedical Devices

Michael V. McConnell(Chief Health Officer and Interim CEO)inFrancesca Logan(Chief Commercial Officer)inYariv Levin(Chief Compliance, Ethics and Clinical Affairs Officer)in

Co-investorsArc AngelsIcehouse VenturesOutset VenturesBlockchain CapitalFunders Club Managementgmjp+8 more

Tokutoku.comin𝕏Apr 2024 · $9.3M

Toku provides payroll infrastructure that lets companies pay teams in stablecoins, fiat, or tokens through a single API that integrates with existing systems like ADP, Gusto, and Workday.

Crypto & Web3Enterprise SoftwareFintechHR TechNew York, US

Kenneth O'Friel(Founder)inDominika Stobiecka(Cofounder)in

Co-investorsBlockchain CapitalFirestreak VenturesWinklevoss CapitalFunders Club ManagementgmjpGradient Ventures+7 more

Tokutoku.coin𝕏Apr 2024 · $9.3M

Toku is a cloud communications provider offering customer experience solutions, including a hosted contact centre (CCaaS) offering, to businesses.

AI & Machine LearningCloud ComputingEnterprise SoftwareSaaSSingapore, SG

Thomas Laboulle(Founder)in

Co-investorsBetatron Venture GroupOSK Ventures InternationalBlockchain CapitalFunders Club ManagementgmjpGradient Ventures+7 more

Other

Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.

Parrot Technologies Inc / DE

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.